Meeting
2024 ASCO Annual Meeting
A phase 1b study of ensartinib in combination with platinum-based chemotherapy and bevacizumab in ALK-positive non-small cell lung cancer (NSCLC).
Authors
Kyle Concannon
The University of Texas MD Anderson Cancer Center, Houston, TX
Kyle Concannon , Giovanni Selvaggi , Joey Zhou , Yasir Y Elamin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
2020-0838
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 8624)
DOI
10.1200/JCO.2024.42.16_suppl.8624
Abstract #
8624
Poster Bd #
488
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
REZILIENT3: Phase 3 study of zipalertinib plus chemotherapy in patients with previously untreated, advanced nonsquamous non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertions (ex20ins) mutations.
First Author: Helena Alexandra Yu
Poster
2019 ASCO Annual Meeting
Efficacy of platinum-pemetrexed combination chemotherapy in ALK+ non-small cell lung cancer refractory to second-generation ALK TKIs.
First Author: Jessica Jiyeong Lin
Poster
2023 ASCO Annual Meeting
A randomized, double blinded, multicenter phase 3 study of platinum-based chemotherapy with or without QL1706 as adjuvant therapy in completely resected stage II-IIIb NSCLC.
First Author: Yuming Zhu
Poster
2022 ASCO Annual Meeting
TRUST-II: A global phase II study for taletrectinib in ROS1 fusion–positive lung cancer and other solid tumors.
First Author: Misako Nagasaka